Oral therapies reshaped multiple sclerosis care, and the S1P receptor modulator class has progressively narrowed its targeting to reduce off-target effects. Ponvory (ponesimod) is among the most selective.
As a selective sphingosine 1-phosphate receptor 1 modulator, Ponvory sequesters lymphocytes in lymph nodes, reducing immune attacks on myelin. The once-daily tablet covers relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Ponvory faces no generic competition but entered a class already served by several established agents. Its head-to-head superiority data against teriflunomide and its receptor selectivity are the main differentiators in MS comparator selection.
